Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Co-administration with Preventive Monoclonal Antibody Treatment
AHSAM 2020 - Poster session
Published on July 17, 2020
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
- Pharmacokinetic parameters of ubrogepant did not change following coadministration with erenumab or galcanezumab.
- There did not appear to be any safety concerns during coadministration with both erenumab and galcanezumab.
- The most common specific adverse event following study intervention was headache in 6 participants following erenumab injection.